NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free SABS Stock Alerts $4.40 +0.04 (+0.92%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$4.40▼$4.4050-Day Range$4.17▼$6.0052-Week Range$4.00▼$11.90Volume731 shsAverage Volume14,921 shsMarket Capitalization$40.61 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get SAB Biotherapeutics alerts: Email Address SAB Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside252.3% Upside$15.50 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.31) to ($6.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector670th out of 907 stocksBiological Products, Except Diagnostic Industry116th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.39% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SAB Biotherapeutics has recently increased by 38.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SABS. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for SABS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.95% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.82% of the stock of SAB Biotherapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to decrease in the coming year, from ($4.31) to ($6.21) per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About SAB Biotherapeutics Stock (NASDAQ:SABS)SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.Read More SABS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SABS Stock News HeadlinesApril 17, 2024 | msn.comSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36April 17, 2024 | americanbankingnews.comSAB Biotherapeutics' (SABS) Buy Rating Reaffirmed at Chardan CapitalApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 17, 2024 | americanbankingnews.comSAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC WainwrightApril 16, 2024 | msn.comSAB Leaps on Completing Latest CohortApril 16, 2024 | globenewswire.comSAB Biotherapeutics Provides SAB-142 Trial UpdateApril 8, 2024 | globenewswire.comSAB Biotherapeutics to Present at INNODIA Annual MeetingApril 4, 2024 | markets.businessinsider.comSAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy RatingApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 4, 2024 | globenewswire.comSAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 29, 2024 | globenewswire.comSAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 25, 2024 | markets.businessinsider.comSAB Collaborates With Naval Medical Research To Develop Potential Influenza Treatment; Stock DropsMarch 25, 2024 | globenewswire.comSAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentFebruary 23, 2024 | globenewswire.comSAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 2, 2024 | marketwatch.comSAB Biotherapeutics Names Samuel Reich Chief ExecutiveFebruary 2, 2024 | markets.businessinsider.comSAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEOFebruary 2, 2024 | finance.yahoo.comSAB Biotherapeutics Announces Executive Leadership ChangeJanuary 24, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 23, 2024 | finance.yahoo.comSAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)January 5, 2024 | finance.yahoo.comIndividual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last weekJanuary 3, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitJanuary 2, 2024 | finance.yahoo.comSAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitSee More Headlines Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/21/2023Today4/24/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone605-679-6980FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+252.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,190,000.00 Net Margins-1,884.10% Pretax Margin-1,884.50% Return on Equity-144.66% Return on Assets-88.65% Debt Debt-to-Equity Ratio0.06 Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$2.24 million Price / Sales18.13 Cash FlowN/A Price / Cash FlowN/A Book Value$6.21 per share Price / Book0.71Miscellaneous Outstanding Shares9,230,000Free Float6,832,000Market Cap$40.61 million OptionableNot Optionable Beta0.80 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Samuel J. Reich (Age 49)CEO & Executive Chairman Comp: $363.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, President & Director Comp: $402.56kMs. Christine E. Hamilton M.B.A. (Age 68)Co-Founder & Independent Director Comp: $25kMr. Michael George King Jr. (Age 63)EVP & CFO Comp: $60.58kDr. Christoph Bausch M.B.A. (Age 53)Ph.D., Executive VP & COO Comp: $443.2kDr. Alexandra Kropotova M.B.A. (Age 51)M.D., Executive VP & Chief Medical Officer Comp: $774.45kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverDr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsCurisNASDAQ:CRISSangamo TherapeuticsNASDAQ:SGMOAgenusNASDAQ:AGENOKYO PharmaNASDAQ:OKYONKGen BiotechNYSE:NKGNView All CompetitorsInsiders & InstitutionsBVF Inc. ILBought 9,178,282 shares on 2/15/2024Ownership: 175.426%RTW Investments LPBought 9,178,282 shares on 2/14/2024Ownership: 175.493%Commodore Capital LPBought 1,831,746 shares on 2/14/2024Ownership: 35.024%Eddie Joe SullivanBought 1,740 shares on 12/7/2023Total: $1,531.20 ($0.88/share)Michael KingBought 5,000 shares on 11/30/2023Total: $4,500.00 ($0.90/share)View All Insider TransactionsView All Institutional Transactions SABS Stock Analysis - Frequently Asked Questions Should I buy or sell SAB Biotherapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SABS shares. View SABS analyst ratings or view top-rated stocks. What is SAB Biotherapeutics' stock price target for 2024? 3 equities research analysts have issued 12 month price objectives for SAB Biotherapeutics' stock. Their SABS share price targets range from $6.00 to $25.00. On average, they predict the company's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 252.3% from the stock's current price. View analysts price targets for SABS or view top-rated stocks among Wall Street analysts. How have SABS shares performed in 2024? SAB Biotherapeutics' stock was trading at $0.6875 at the start of the year. Since then, SABS stock has increased by 540.0% and is now trading at $4.40. View the best growth stocks for 2024 here. Are investors shorting SAB Biotherapeutics? SAB Biotherapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 28,900 shares, an increase of 38.3% from the March 15th total of 20,900 shares. Based on an average daily volume of 17,400 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.4% of the shares of the stock are sold short. View SAB Biotherapeutics' Short Interest. When is SAB Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our SABS earnings forecast. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) released its quarterly earnings data on Monday, August, 21st. The company reported ($0.14) EPS for the quarter, meeting analysts' consensus estimates of ($0.14). The business earned $0.09 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,884.10% and a negative trailing twelve-month return on equity of 144.66%. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SABS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
